Guardant Health, Trial Library Partner to Expand Access to Cancer Clinical Trials

Original from: genomeweb

Guardant Health announced Thursday that it has partnered with artificial intelligence firm Trial Library to expand access to cancer clinical trials across the US. 

The collaboration will combine Guardant's suite of precision oncology diagnostics with Trial Library's artificial intelligence-powered matching and patient navigation platform. The companies intend to streamline the identification, referral, and enrollment of patients into precision oncology clinical trials, allowing providers to offer new treatment opportunities to a broader and more representative patient population, Guardant said in a statement. 

Guardant's real-world data capabilities will help identify relevant patients for clinical trials based on biomarker and clinical data, while Trial Library's platform provides access to clinical trials in community-based clinical settings across the US through provider activation, compliant eligible patient identification, and longitudinal navigation throughout the trial life cycle. 

"Precision oncology only works if patients can actually access the treatments being developed," Guardant Health Chairman and co-CEO Helmy Eltoukhy said in a statement. "With Trial Library, we're linking biomarker insights directly to real trial opportunities and providing the support patients need to act on them. Together, we can close the gap between genomic discovery and equitable participation in lifesaving research."

Source: Guardant Health, Trial Library Partner to Expand Access to Cancer Clinical Trials